Millennium Management’s Benitec Biopharma BNTC Stock Holding History

Millennium Management’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.94M	Buy	652,064 +38,904	+6%	+$450K	﹤0.01%	2573
2025 Q4	$8.26M	Buy	+613,160	New	+$8.48M	﹤0.01%	2469
2025 Q2	–	Sell	-32,046	Closed	-$417K	–	5875
2025 Q1	$417K	Buy	+32,046	New	+$388K	﹤0.01%	4915
2022 Q4	–	Sell	-3,070	Closed	-$19K	–	6582
2022 Q3	$19K	Buy	3,070 +1,592	+108%	+$20.2K	﹤0.01%	6474
2022 Q2	$29K	Buy	+1,478	New	+$34.4K	﹤0.01%	6380

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management's BNTC Position: Q1 2026 in Review

Millennium Management increased its Benitec Biopharma (BNTC) stake by 6.3% in Q1 2026, buying an estimated $450K and bringing the position to 652,064 shares worth $6.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2573.

Millennium Management first reported a position in BNTC in Q2 2022 and has held it in 5 quarters since. The position peaked at $8.26M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Millennium Management held 652,064 shares of Benitec Biopharma worth $6.94M as of Q1 2026.
Millennium Management bought 38,904 Benitec Biopharma shares in Q1 2026, an estimated $450K.
Benitec Biopharma made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2573 holding.
Millennium Management first reported a position in Benitec Biopharma in Q2 2022 and has held it in 5 quarters since.
Millennium Management's Benitec Biopharma position peaked at $8.26M in Q4 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.